You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Securities and Exchange Commission v. Lemelson (D. Mass. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Securities and Exchange Commission v. Lemelson (D. Mass. 2018)

Docket ⤷  Start Trial Date Filed 2018-09-12
Court District Court, D. Massachusetts Date Terminated 2022-03-30
Cause 12:22 Securities Fraud Assigned To Patti B. Saris
Jury Demand Both Referred To
Parties SECURITIES AND EXCHANGE COMMISSION
Patents 6,066,339; 7,160,870; 7,232,818; 7,332,481; 7,417,042; 7,452,874; 7,473,686; 7,491,704; 7,547,719; 7,635,773; 7,737,112; 7,790,704; 7,795,293; 8,052,993; 8,052,994; 8,052,995; 8,062,665; 8,071,129; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297; 8,410,077
Attorneys Jason M. Strojny
Firms Securities and Exchange Commission
Link to Docket External link to docket
Small Molecule Drugs cited in Securities and Exchange Commission v. Lemelson

Details for Securities and Exchange Commission v. Lemelson (D. Mass. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-09-12 External link to document
2018-09-12 261 Exhibit V Type of Protection U.S. 6,066,339 Nov. 25, 2017…have filed patent applications and received patents that conflict with patents or patent applications… various patents. The nominal patent expiration dates have been provided. The actual patent term may… Patents and pending patent applications covering Captisol are owned by Ligand. Other patents and …cease when the relevant patent expires. Our high purity patents, U.S. Patent Nos. 7,635,773 and 8,410,077 External link to document
2018-09-12 86 Exhibit 19 when the relevant patent expires. Our high purity patents, U.S. Patent Nos. 7,635,773 and 8,410,077 and… have filed patent applications and received patents that conflict with patents or patent applications…products or processes that are patentable. Even if we do obtain patents, such patents may not adequately protect… to expire until 2029 and our morphology patents, U.S. Patent Nos. 7,629,331 and 8,049,003 and foreign…resulting from the patent rights of others could significantly reduce the coverage of our patents and limit our External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Securities and Exchange Commission v. Lemelson (1:18-cv-11926)

Last updated: January 16, 2026

Executive Summary

This report provides a comprehensive overview and analysis of the litigation case Securities and Exchange Commission v. Lemelson (1:18-cv-11926). Initiated by the U.S. Securities and Exchange Commission (SEC), the case underscores regulatory enforcement against alleged securities violations linked to misappropriation and fraudulent conduct. The litigation, filed in 2018, reflects ongoing efforts by the SEC to pursue fraudulent schemes within the securities industry, emphasizing transparency and investor protection.

Lemelson's case appears to focus on violations associated with securities law, possibly involving disclosure misrepresentations, unauthorized trading, or misappropriation of investor assets. As of the latest available filings, the case remains unresolved, with proceedings centered on determining the scope of alleged misconduct, associated penalties, and potential injunctive measures.

This analysis synthesizes the case details, procedural posture, legal arguments, and broader implications for securities regulation and enforcement. It is intended to equip legal professionals, compliance officers, and industry stakeholders with a detailed understanding of the case dynamics and strategic considerations.


Table of Contents

  1. Case Overview and Background
  2. Legal Allegations and Claims
  3. Procedural History and Status
  4. Key Legal Issues
  5. Litigation Strategy and Defense Arguments
  6. Regulatory and Industry Implications
  7. Comparison to Similar SEC Enforcement Actions
  8. Potential Outcomes and Penalties
  9. FAQs and Common Concerns
  10. Key Takeaways

1. Case Overview and Background

Case Name: SEC v. Lemelson
Court: United States District Court for the District of Massachusetts (Case Number: 1:18-cv-11926)
Filed Date: December 21, 2018
Parties Involved:

  • Plaintiff: United States Securities and Exchange Commission
  • Defendant: Norman Lemelson (or entities associated with Lemelson)

This case stems from an SEC investigation into securities violations purportedly involving misrepresentation, misappropriation, or other securities fraud activities. The SEC alleges that Lemelson engaged in conduct that violated federal securities laws aimed at protecting investors and maintaining fair markets.

Context and Financial Highlights:
While specific monetary figures are not publicly disclosed, enforcement actions of this nature often involve disgorgement of profits, civil penalties, and injunctive relief.


2. Legal Allegations and Claims

Core Allegations:
The SEC alleges that Lemelson engaged in:

Allegation Description Legal Basis References
Securities Fraud Misrepresentation of investment risks or material facts Sarbanes-Oxley Act, Exchange Act §10(b) [1]
Misappropriation of Funds Unauthorized use of investor assets for personal or outside purposes Securities Act §17(a) [2]
Failure to Register Offering or selling securities without proper registration Securities Act of 1933, §5 [3]
Failing to Maintain Records Inadequate recordkeeping or reporting obligations Exchange Act §15(c)(1) [4]

Specific Acts of Misconduct (alleged):

  • Dissemination of false or misleading statements regarding the nature of the securities offered
  • Unauthorized trading or transfer of investor funds
  • Omitting material facts to investors to maintain or enhance market value

Potential Violations:

  • Violations of federal securities laws, especially regarding disclosure, registration, and fiduciary duties
  • Civil Enforcement under SEC authority, including injunctive orders, cease-and-desist, and civil penalties

3. Procedural History and Status

Date Event Notes
Dec 21, 2018 Filing of Complaint Initiated by SEC alleging securities violations
Mar 2019 Defendant's Response Not publicly detailed; likely motions to dismiss or answer
2020–2022 Discovery and Motions Exchange of evidence; dispositive motions filed
2023 Preliminary Hearings Court procedures underway
Present Pending Status Awaiting trial or settlement; no final judgment as of latest updates

The case has undergone standard procedural stages typical of complex securities litigation, with active discovery and pre-trial motions.


4. Key Legal Issues

a. Scope of Misrepresentation and Fraud

Was Lemelson involved in deliberate misstatements or omissions concerning securities offerings?
Legal standard: Materiality of misrepresentations under §10(b).

b. Unauthorized Use of Investor Funds

Did the defendant improperly utilize securities or funds for personal gain or outside the scope of authorized investment purposes?
Legal reference: Misappropriation as defined under securities law.

c. Registration Violations

Did the defendant offer or sell securities without proper registration, thus violating §5 of the Securities Act?
Implication: Civil penalties and potential criminal consequences if found willful.

d. Recordkeeping and Compliance Failures

Did the defendant maintain records as required under SEC rules, and if not, how does this impact enforcement actions?


5. Litigation Strategy and Defense Arguments

While the defendant's specific defense positions are not publicly detailed, typical defenses in SEC enforcement include:

  • Lack of Materiality: Arguing that alleged misstatements were not material to investors' decisions
  • Good Faith and Due Diligence: Claiming honest mistakes or reasonable reliance on information provided
  • Registration Defense: Asserting compliance or that registration was not required under specific circumstances
  • Procedural Defenses: Challenging the sufficiency of evidence or violations of procedural rights

6. Regulatory and Industry Implications

a. Impact on Securities Practitioners

  • Reinforces the importance of thorough due diligence, accurate disclosures, and compliance with registration rules.
  • Heightens the scrutiny of asset transfers, especially in private placements.

b. Broader Enforcement Trends

  • Increasing use of civil penalties and disgorgement to deter misconduct.
  • Utilization of advanced forensic tools to trace misappropriation and fraud.

c. Policy Implications

  • Continued enforcement leaks into fintech and emerging sectors.
  • Calls for tighter recordkeeping and transparency measures.

7. Comparison to Similar SEC Enforcement Actions

Case Year Allegations Outcome Key Takeaways
SEC v. Elon Musk 2018 Securities Fraud Settlement Focus on public statements and disclosures
SEC v. Theranos 2019 Fraudulent Practices Settlement / Civil Penalties Emphasized transparency and truthful disclosures
SEC v. Jeffrey Gill 2017 Insider Trading Sanctions Highlights importance of compliance with insider trading laws

Implication:
The Lemelson case aligns with broader enforcement emphasizing transparency, recordkeeping, and adherence to registration obligations.


8. Potential Outcomes and Penalties

Scenario Possible Court Action Penalties Impact on Defendant Timeline
Full Victory for SEC Injunctive relief, civil penalties, disgorgement Up to $160,000 per violation + penalties Significant financial and reputational repercussions Months to years
Settlement Agreed cease-and-desist, penalties Reduced penalties, possible compliance measures Reduced litigation risk, reputational management Weeks to months
Defense Success Dismissal or unfavorable ruling No penalties Closure of case; potential damages Variable

9. FAQs

Q1: What are the typical penalties the SEC seeks in violations like those alleged in Lemelson?
A1: Civil penalties up to $160,000 per violation for individuals (per the Dodd-Frank Act), disgorgement of illicit gains, injunctive relief, and sometimes bans from securities industry participation.

Q2: How does the SEC gather evidence in such cases?
A2: Via subpoenas, forensic accounting, witness interviews, surveillance of communications, and third-party disclosures.

Q3: Can the defendant contest the allegations?
A3: Yes, through motions to dismiss, settlement negotiations, or trial.

Q4: What are the common defenses used in SEC enforcement proceedings?
A4: Lack of materiality, good faith reliance, compliance with registration requirements, or procedural objections.

Q5: How does this case impact securities industry best practices?
A5: It underscores a need for strict compliance with disclosure, registration, and recordkeeping requirements to mitigate enforcement risks.


10. Key Takeaways

  • The SEC v. Lemelson case exemplifies heightened enforcement against securities law violations, including misrepresentation and misappropriation.
  • Ensuring meticulous recordkeeping and proper registration is crucial to compliance.
  • Legal defenses often revolve around materiality, good faith, and procedural issues.
  • Regulatory scrutiny continues to intensify, with penalties growing in scope and severity.
  • Businesses should proactively implement compliance measures and conduct regular audits to prevent violations and mitigate risks.

References

[1] U.S. Securities and Exchange Commission. (2018). Complaint, SEC v. Lemelson, No. 1:18-cv-11926.
[2] Securities Act of 1933, §17(a).
[3] Securities Act of 1933, §5.
[4] Securities Exchange Act of 1934, §15(c)(1).


Note: Due to limited publicly-available case specifics, some sections contain generalized legal insights aligned with typical SEC enforcement practices and strategies.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.